Journal of Pulmonology and Respiratory Research最新文献

{"title":"Non-smoking woman with adenocarcinoma of the lung, IV stage with ROS1 mutation and acquired thrombophilia","authors":"I. Taivāns, Natalja Senterjakova, V. Kozirovskis, G. Strazda, Jurijs Nazarovs, V. Gordjušina","doi":"10.29328/journal.jprr.1001027","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001027","url":null,"abstract":"Despite the fact, that lung cancer is more common among older smoking men, however it may also develop among young women without a smoking anamnesis. We report here a history of a non-smoking woman, 40 years old, with a diagnosis of lung adenocarcinoma at IV stage. Despite the fact, the woman received three lines of palliative chemotherapy, the disease progressed. After the sample of the tumor was tested by genetic approach, ROS1 mutation was detected, and the patient was treated with a ROS1 inhibitor, Crizotinib. Sharp improvement was observed already after the first week of treatment. After one-month adenocarcinoma shrink, and specific supraclavicular lymph nodes disappeared. Unfortunately, due to problems with financing the treatment was stopped, after what the disease began to progress rapidly, and the patient died after a month due to brain metastasis. This case is noteworthy also because the patient was first diagnosed a thrombophilia with thrombi present in deep calf veins, left heart ventricle and lungs Adenocarcinoma was discovered occasionally when during video-assisted thoracoscopic surgery biopsy specimen was taken from suspicious mass in the lower lobe of the right lung. This story reminds us that lung carcinoma may start with a paraneoplastic syndrome, like thrombophilia as in this case and finding of adenocarcinoma of the lung in young, non-smoking persons is indicative for possible ROS1 gene mutation. In such cases early treatment with ROS1 protein-tyrosine kinase inhibitors should be started as soon as possible.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"32 9","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120922174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Vanishing” breast implant – when a breast prosthesis is moving into the pleural cavity","authors":"Gries Thomas, Popp Daniel, Raab Stephan, Berghaus Thomas","doi":"10.29328/journal.jprr.1001028","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001028","url":null,"abstract":"The female patient was thought to have a so-called destroyed lung syndrome, but malignancy remains within the scope, however. Consequently, she has been operated on, applying an atypical partial wedge resection by means of open thoracotomy surgery in April 2020. Fortunately, inal histological evaluation could exclude both lung carcinoma and metastases to the lung. In brief, destroyed lung syndrome is an end-stage destructive and suppurative lung disorder secondary to essentially infectious diseases, leading to necrotizing pneumonia [1]. Resective surgery was urgently needed because of ongoing immunotherapy due to previously known lymphatic spread of metastasizing breast carcinoma.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127965174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case series on Asthma-COPD overlap (ACO) is independent from other chronic obstructive diseases (COPD and Asthma)","authors":"Divya Khanduja, Naveen Pandhi","doi":"10.29328/journal.jprr.1001025","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001025","url":null,"abstract":"As we know that, Asthma and chronic obstructive pulmonary diseases are well characterized diseases, they can co-exist as asthma-COPD overlap (ACO). The co-existence of asthma-chronic obstructive pulmonary disease overlap (ACO) in chronic obstructive pulmonary disease (COPD) patients is often unrecognized. In patients with a primary diagnosis of COPD or Asthma, the identification of ACO has got implication for better prognosis and treatment. Such patients experience frequent exacerbations, poor quality of life, rapid decline in lung function and high mortality than COPD or Asthma alone. Inhalational steroids provide significant alleviation of symptoms in such patients and some studies suggest that the most severe patients may respond to biological agents indicated for severe asthma. Patients who have asthma with a COPD component tend to present with severe hypoxia because of Irreversible/fixed airway obstruction and impairment of the alveolar diffusion capacity by emphysematous changes. In contrast, patients with COPD who have an asthma component not only have exertional dyspnoea but also develop paroxysmal wheezing or dyspnoea at night or in the early morning. The criteria to diagnose asthma-COPD overlap (ACO) include positive bronchodilator response, sputum eosinophilia or previous diagnosis of asthma, high IgE and/or history of atopy. There is scarcity of literature available in country like India. We highlight the importance of identification of Asthma COPD overlap as different phenotype from COPD or asthma alone as it is challenging to diagnose ACO in India. We report 3 cases having both the features of asthma and COPD, later diagnosed with Asthma-COPD overlap.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"140 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116728178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary mucormycosis in post-pulmonary tuberculosis as an emerging risk factor: A rare case report","authors":"Divya Khanduja, Naveen Pandhi","doi":"10.29328/journal.jprr.1001026","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001026","url":null,"abstract":"Pulmonary mucormycosis is an uncommon pulmonary fungal disease, which is commonly seen in immunocompromised individuals. It is caused by fungi of class Zygomycetes. It constitutes the third most common invasive fungal infection following aspergillosis and candidiasis. Risk factors include patients with hematological malignancies, diabetes mellitus, and immunocompromised states. It is difficult to diagnose early due to non-specific clinical presentation and delay in treatment associated with greater mortality. As we know that Tuberculosis and HIV are highly prevalent in country like India. Post pulmonary tuberculosis is emerging as a risk factor for Pulmonary mucormycosis in the developing countries like India. Patients with non-resolving pneumonia are generally misdiagnosed as Pulmonary tuberculosis. The diagnosis of Pulmonary Mucormycosis is based upon demonstration of fungal hyphae in the clinical specimen. We highlight the importance of clinical suspicion in these cases for early diagnosis and early treatment initiation can reverse morbidity and mortality associated with Pulmonary Mucormycosis. We report 2 cases of Pulmonary mucormycosis present in post-pulmonary tuberculosis patients.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"289 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134320666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organizing pneumonia as the initial presentation in rheumatoid arthritis – A case report","authors":"Kaur Harveen, Singh Dilbag, P. Naveen","doi":"10.29328/journal.jprr.1001024","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001024","url":null,"abstract":"Organizing pneumonia (OP), can be seen in association with lung injury, infection, drug intoxication, and connective tissue diseases. Patients of rheumatoid arthritis (RA) are prone to develop interstitial lung disease (ILD), but the pulmonary involvement usually occurs several years after the joint manifestations. Only in about 10% cases of RA, the initial manifestation of the disease can be in the form of interstitial lung disease. OP as the initial manifestation of RA is extremely uncommon occurrence. Here is presented a case of 52-year-old male who presented with OP as the initial manifestation of RA. On investigation, the RA factor and anti-CCP Antibodies were positive. Based on clinical, radiological and histopathological findings the diagnosis was established.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117085583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystic fibrosis, the key link with airborne alpha emitting nanoparticulates","authors":"Pirot Florent","doi":"10.29328/journal.jprr.1001023","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001023","url":null,"abstract":"Cystic fibrosis is explained in this paper that suggests tackling the disease by elimination of the most significant sources of contamination.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114914830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic fatigue syndrome and epigenetics: The case for hyperbaric oxygen therapy in biomarker identification","authors":"Rajit J Shah","doi":"10.29328/JOURNAL.JPRR.1001020","DOIUrl":"https://doi.org/10.29328/JOURNAL.JPRR.1001020","url":null,"abstract":"Chronic fatigue syndrome (CFS) is a poorly-understood respiratory condition that affects millions of individuals. Hyperbaric oxygen therapy (HBOT) is a treatment option being considered to address CFS as it is suggested to combat fatigue and increase oxygenation. HBOT provides two opportunities in advancing research of CFS: it may provide data on symptom amelioration and be utilized in the search for a biomarker. By either identifying biomarkers before using HBOT to compare epigenomes of patients before and after treatment or using HBOT to find epigenetic discrepancies between patients with and without treatment, matching epigenetic regulation with symptom amelioration may significantly advance the understanding of the etiology and treatment mechanism for CFS. EPAS1/HIF-2α is a leading candidate for an epigenetic biomarker as it responds differentially to hypoxic and normoxic conditions, which degrades more slowly in hypoxic conditions. Epigenetic regulation of EPAS1/HIF-2α in such differential conditions may be explored in HBOT experiments. In addition to HBOT as a promising treatment option for CFS symptoms, it may aid the identification of biomarkers in CFS. Further research into both outcomes is strongly encouraged.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"116 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117211430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Involvement in COVID-19 and ‘Long Covid’: The Morbidity, Complications and Sequelae","authors":"Nikhra Vinod","doi":"10.29328/journal.jprr.1001022","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001022","url":null,"abstract":"Introduction: the perennial pandemic: There are serious challenges posed by the SARS-CoV-2 virus and COVID-19 as the disease. With the persistence of the pandemic over one and half year, it is being feared that the COVID-19 may have become the new reality associated with human existence world over and the mankind may have to live with it for years or even decades. Further, the grievous nature of the disease is evolving further with genomic changes in the virus in form of mutations and evolution of variants, with enhanced infectivity and probably virulence. Acute and chronic phases of COVID-19: Epidemiologically, it is becoming clear that apart from the advanced age and pre-existing conditions, such as diabetes, cardiovascular, pulmonary, and renal diseases, certain constituent factors render some patients more vulnerable to more severe forms of the disease. These factors influence the COVID-19 manifestations, its course, and later the convalescence period as well as the newly defined ‘Long COVID phase. The substantial continuing morbidity after resolution of the infection indicates persisting multisystem effects of ‘Long Covid’. Lung damage associated with COVID-19: COVID-19 is primarily a respiratory disease presenting with a broad spectrum of respiratory tract involvement ranging from mild upper airway affliction to progressive life-threatening viral pneumonia and respiratory failure. It affects the respiratory system in various ways across the spectrum of disease severity, depending on age, immune status, and comorbidities. The symptoms may be mild, such as cough, shortness of breath and fevers, to severe and critical disease, including respiratory failure, shock, cytokine crisis, and multi-organ failure. Implications for the post-COVID care: Depending on the severity of respiratory inflammation and damage, as well as associated comorbidities, duration of injury and genetics, the progressive fibrosis leads to constriction and compression of lung tissues and damage to pulmonary microvasculature. Consequently, the COVID-19 patients with moderate/severe symptoms are likely to have a significant degree of long-term reduction in lung function. Depending on the severity of the disease, extensive and long-lasting damage to the lungs can occur, which may persist after resolution of the infection. Managing the long COVID’s challenges: Given global scale of the pandemic, the healthcare needs for patients with sequelae of COVID-19, especially in those with lung affliction are bound to increase in the near future. The challenge can be tackled by harnessing the existing healthcare infrastructure, development of scalable healthcare models and integration across various disciplines with a combination of pharmacological and non-pharmacological modalities. Following clinical and investigational assessment, the therapeutic strategy should depend on the disease manifestations, extent of damage in lungs and other organs, and associated complications.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122251218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysfunctional breathing in children","authors":"A. Trompenaars, Aalt Pj Van Roest, A. Vaessen-Verberne","doi":"10.29328/journal.jprr.1001013","DOIUrl":"https://doi.org/10.29328/journal.jprr.1001013","url":null,"abstract":"Dysfunctional breathing (DB) describes a group of abnormal breathing patterns. The de inition of DB is unclear and no gold standard exists for diagnosis. Symptoms include hyperventilation, breathlessness, chest tightness and chest pain, but also anxiety, light-headedness and fatigue. Besides these symptoms, patients may also exhibit unsteadiness, exercise intolerance, frequent sighing and predominantly non-diaphragmatic respiratory efforts [1,2]. DB may result in either intermittent or chronic complaints. DB often remains undetected or may be falsely diagnosed as asthma, and may therefore be responsible for a serious burden of morbidity and unnecessary medication use.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114126516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Prevalence of Tuberculosis in the State of Maranhão between 2014 and 2016","authors":"Pad Miranda Neto, HB de Melo Santana, VM das Neves, H. Maia, T. França, R. Costa","doi":"10.29328/JOURNAL.JPRR.1001012","DOIUrl":"https://doi.org/10.29328/JOURNAL.JPRR.1001012","url":null,"abstract":"Tuberculosis (TB) is an infectious-contagious disease and is considered the second leading cause of death in the world, second only to HIV [1]. Approximately 2 billion people were infected with Mycobacterium tuberculosis, and in 2012, almost 8.6 million people developed TB, causing the death of 1.3 million, posing a challenge for health authorities to eliminate TB by 2050 [2]. In Maranhão, for example, of its 217 municipalities, eight were prioritized: Caxias, Codó, Imperatriz, Açailândia, Paço do Lumiar, São Luís, São José de Ribamar and Timon because they had a population of more than 100,000 inhabitants and a high bacillary load, State of Maranhão, by the Ministry of Health, for the control of TB [3]. São Luís, the state capital, accounts for 40% of total noti ications among priority municipalities, with 585 cases annually in the last ten years, in which the most prevalent clinical form is lung disease [4]. Human tuberculosis (TB) is caused by some Mycobacterium tuberculosis Complex Microbacteria (CMTB), and the causative agent needs molecular oxygen to grow and multiply. The etiologic agent is Mycobacterium tuberculosis, known as Bacillus de Koch (BK), and presents a chronic evolution affecting the lungs frequently. The spread of infection occurs through contaminated biological material, mainly aerosols from coughing or sneezing [5-7]. Mycobacterium tuberculosis is a mycobacterium belonging to the genus Mycobacterium, from the Mycobacteriaceae family [8]. CMTB species are responsible for TB in humans and animals, with seven species of this complex: M.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129665492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}